Detalhe da pesquisa
1.
Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 study.
Am J Hematol
; 98(4): 645-657, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36606708
2.
Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2.
Br J Cancer
; 118(3): 344-352, 2018 02 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29337963
3.
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors.
Invest New Drugs
; 36(4): 619-628, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29094232
4.
Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.
Br J Cancer
; 116(12): 1505-1512, 2017 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28463960
5.
Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials.
Invest New Drugs
; 35(1): 79-86, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27783256
6.
Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors.
BMC Cancer
; 17(1): 547, 2017 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28810837
7.
Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies.
Oncology
; 90(1): 10-20, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26492090
8.
Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large B-cell lymphoma: Results of LNH-EP1 study.
Am J Hematol
; 96(10): E376-E379, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34165816
9.
Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours.
Br J Cancer
; 113(10): 1413-20, 2015 Nov 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-26512876
10.
Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors.
Invest New Drugs
; 32(6): 1188-96, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24898305
11.
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review.
Eur J Cancer
; 205: 114075, 2024 May 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38733717
12.
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial.
Clin Cancer Res
; 2024 May 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38771739
13.
Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis?
Eur Respir J
; 51(1)2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29301923
14.
Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma.
Clin Cancer Res
; 29(17): 3320-3328, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37382656
15.
Single-agent gemcitabine in patients with advanced, pre-treated angiosarcoma: A multicenter, retrospective study.
Cancer Med
; 12(3): 3160-3166, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35971325
16.
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer.
Cancer Discov
; 13(9): 1998-2011, 2023 09 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37377403
17.
Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study.
Cancer Discov
; 12(2): 402-415, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34551969
18.
Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials.
Eur J Cancer
; 163: 98-107, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35063776
19.
Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers.
J Exp Clin Cancer Res
; 41(1): 217, 2022 Jul 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35794623
20.
Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.
Front Immunol
; 12: 775761, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34925348